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ORIGINAL ARTICLE
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ABSTRACT
Objectives: The aim of this study was to determine the prevalence of liver fibrosis in
patients with human immunodeficiency virus (HIV) monoinfection versus those with HIV
hepatitis‑B virus (HBV) co‑infection as assessed with shear wave elastography (SWE)
in a tertiary sub‑Saharan Africa hospital. Materials and Methods: A total of 105
consecutive patients, 70 with HIV monoinfection and 35 with HIV‑HBV co‑infection,
had liver elastography obtained using SWE to assess for the presence of liver fibrosis
the cutoff of which was 5.6 kPa. Assessment of aspartate aminotransferase‑to‑platelet
ratio index (APRI) score (a noninvasive serum biomarker of liver fibrosis) in these
patients was also done. Results: The prevalence of liver fibrosis was significantly higher
(P < 0.0001) in patients with HIV‑HBV co‑infection, 25.7%, compared to those with HIV
monoinfection, 7.1%. APRI score was greater in patients with HIV‑HBV co‑infection
than those with HIV monoinfection. HIV co‑infection with HBV accelerates progression
to liver fibrosis. Association of a low cluster of differentiation 4 (CD‑4) count with
advanced fibrosis supports earlier starting of antiretroviral therapy to prevent rapid
progression of liver disease in HIV‑positive patients. Conclusion: In view of the high
prevalence of liver fibrosis in patients with HIV‑HBV co‑infection, regular monitoring
of the disease progression is recommended.
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INTRODUCTION

MATERIALS AND METHODS

Liver disease in the last decade has become one of the
leading causes of morbidity and mortality in human
immunodeficiency virus (HIV) infected individuals with
chronic liver disease emerging as the leading cause of
nonacquired immunodeficiency disease syndrome‑related
deaths in this population.[1] Chronic hepatitis‑B virus (HBV)
infection in patients with HIV occurs at a rate ten times
higher than in the general population and is associated
with increased rate of progression to chronic liver disease.[2]

This was a cross‑sectional study at a tertiary hospital. The
study obtained approval from the institution’s research
and ethics committee and written informed consent
was obtained from all participants before enrollment in
this study. Inclusion criteria were HIV‑positive patients
attending the HIV clinic at the tertiary hospital who
consented to the study and had HBV and hepatitis‑C
virus (HCV) tests. Patients with HIV‑HCV co‑infection,
massive ascites, those unable to hold their breath for
adequate elastography readings, and those <18 years of
age were excluded. The acquisition time for the machine
used in this study is typically on the order of 100 ms
which means none‑overt breathing does not affect
the readings. The technique also detects significant
motion with no measurement recorded when there is a
significant motion during the acquisition. One patient
was excluded based on inability to acquire adequate
readings.

Management of chronic liver disease is dependent on the
grade of liver fibrosis to ascertain the urgency and choice
of treatment and advice on further screening for cirrhosis
and hepatocellular carcinoma. Though liver biopsy has
traditionally been the gold standard for diagnosis and staging
of liver fibrosis, the procedure has paramount shortfalls as a
medical screening test. It lacks the safety profile, accuracy,
and accessibility of a standard medical screening test. As a
result, screening for liver fibrosis in patients with HIV is low.
The low prevalence of liver disease staging in these patients
probably contributes to their poor outcome.
In response to the lack of an ideal screening tool for liver
fibrosis, there has been a quest to develop noninvasive
methods for diagnosing fibrosis and cirrhosis in the
last decade. In this respect, there has been significant
development of special blood parameters and
elastography. Serum biomarkers, such as aspartate
aminotransferase (AST )‑to‑platelet ratio index (APRI)
score and elastography are validated tools for assessment
of liver fibrosis. [3,4] These noninvasive methods have
several advantages over liver biopsy including lack of
adverse effects, reduced sampling error, objectivity in the
interpretation of results, and appropriateness for repeated
examinations, all at a lower cost.[5]
Elastography has already been approved by most European
countries as an evaluation tool for liver fibrosis in patients
with viral hepatitis.[6]

Between August 2013 and January 2014, 105 patients were
enrolled in the study. The HIV and HBV infections were
determined using enzyme immunoassay. Chronic HBV
infection was determined by a positive hepatitis‑B surface
antigen for more than 6 months. Based on these tests, two
groups of patients were identified: Seventy patients with
HIV monoinfection and thirty five patients with HIV‑HBV
co‑infection [Figure 1].
Each group had real‑time SWE of the liver performed at the
radiology department of the hospital. Only one machine,
Phillips iU22 xMATRIX, was used for the liver elastography
using a 5 MHz curvilinear probe. The liver elastography was
carried out by one of two consultant radiologists in the
radiology department with ultrasonography experience
of 19 years and 7 years, respectively, a senior resident in
the radiology department with 3 years’ experience or by
a sonographer who has over two decades of experience.
They underwent 3 weeks training on performance of
elastography which was carried out by a specialist.

In Africa, information on liver disease in HIV beyond liver
enzyme measurements have not been studied.[7] Though
the burden of HIV‑HBV co‑infection is known to be higher
in sub‑Saharan Africa as compared to the West, there is a
paucity of data regarding its effect on chronic liver disease
in this group of patients.[8]
The aim of this study was to determine the prevalence
of liver fibrosis in patients with HIV monoinfection as
compared to those with HIV‑HBV co‑infection using shear
wave elastography (SWE) at a Tertiary Teaching Hospital
in Kenya.
2

Figure 1: Flow chart showing process of recruitment of patients.
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Real‑time SWE has been shown to have high intra‑observer
and inter observer reproducibility between an expert
operator and a novice operator.[9,10]
The persons performing the scans were blind to the
liver function tests of the patients. All liver stiffness
measurements (LSMs) were acquired with the patient
lying supine. In each patient and at the same session,
10 LSMs were acquired from the right lobe of the liver
through an intercostal space with the probe in the region
of the midclavicular line. The SWE box was placed at
least 2.0 cm from the liver capsule. The area of the SWE
box was 1 cm 2 and was the same for all patients. Prior
to starting the measurements, patients were trained on
breath‑hold to reduce erroneous readings resulting from
inspiration. Each LSM acquisition took approximately
5 s. The acquisition was from an area free of large vessels
[Figure 2a and b]. This technique reduces the effects of
reverberation artifacts arising from the liver capsule and
pulsations from large vessels on the measurements which
could lead to erroneously high elastography readings.
The median value of ten consecutive measurements in
kilopascals (kPa) was used for statistical analyses.
The measurements obtained were automatically stored in
the department’s picture archiving and communication
systems and also recorded in a data sheet. The data
were then classified into two with elastography scores
<5.6 kPa classified as having no significant fibrosis and
scores ≥5.6 kPa representing the presence of fibrosis.
Elastographic reference ranges have been developed for
distinguishing presence or absence of fibrosis and the
presence of cirrhosis using histology as the reference
standard. [11‑13] Based on these studies, the following
cutoffs have been recommended for elastographic
scores in liver fibrosis using SWE: On average, 5.6 kPa
represents the upper limit for normal, 7.1 kPa the cutoff
for significant fibrosis, while 12 kPa is the cutoff for the
presence of cirrhosis.
a

b

Calculation of the APRI score was done using the
most current AST and platelet count available for the
patient. These were within 3 months of the elastography
measurement. For patients with more than one set of
laboratory test results available, the set of results closest
to the time of the elastography were used. These data were
obtained from a computerized medical register. The score
was then calculated using Wai’s formula:[3]

( AST / upper limitof normalfor AST ) × 100

(

Plateletcount × 109 / L

)

Based on their APRI score, patients were placed into one
of three classes as follows ‑ Class 1: <0.5, Class 2: 0.51–1.5,
and Class 3: >1.5.

Statistical analysis
Study data were captured in a spreadsheet (Excel,
Microsoft Corporation). The analysis was done using STATA
version 11.2 StataCorp, Texas, USA.
The continuous metric data obtained from APRI and SWE
converted to categorical ordinal data using standard
cut‑offs as explained in the methods above.
Differences in baseline characteristics between patients
with and without liver fibrosis by SWE were assessed
using Chi‑square or Fisher’s exact tests, as indicated,
for categorical data and Wilcoxon rank‑sum tests for
continuous data.
Prevalence of liver fibrosis as assessed by SWE was
calculated by dividing the number of patients with liver
fibrosis based on SWE cutoff score with the total number
of patients who had undergone the test.
Association between risk factors such as a low cluster of
differentiation 4 (CD4), cell count (below 200 cells/mm3),
detectable HIV viral load (HIV viral load > 40 copies/mL), and
obesity, with liver fibrosis, were assessed by stratification
and summary odds ratios presented using Mantel‑Haenszel
method. Those found to have a significant effect were
subjected to multivariable logistic regression to control
for the confounding. Pearson’s correlation coefficient was
used to assess for correlation between SWE and APRI score.
Differences and associations were considered statistically
significant if the P value was <0.05.

RESULTS
Figure 2: 43‑year‑old male with human immunodeficiency virus
monoinfection (a) Grayscale liver ultrasound image shows acquisition of liver
stiffness measurement using shear wave elastography. The sample box (arrow)
is away from the liver capsule and large blood vessels. (b) A table shows
summary of ten liver stiffness measurement readings of the same patient with
a median elastography score (encircled) of 2.75 kPa.
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Baseline characteristics
A total of 105 participants were consecutively enrolled; 70
with HIV monoinfection and 35 with HIV‑HBV co‑infection.
All patients were on highly active antiretroviral therapy. The
Journal of Clinical Imaging Science | Vol. 6 | Issue 2 | Apr‑Jun 2016
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baseline characteristics of the two groups are provided in
Table 1. 59% were male, and this was not statistically different
between the two groups. The median age was also similar in
the two groups. The body mass index (BMI) was statistically
lower in patients with HIV‑HBV co‑infection (P < 0.02).
The median AST and alanine aminotransferase (ALT )
were significantly higher in the HIV‑HBV co‑infected
group (P = 0.001 and P = 0.002, respectively).
At the time of enrollment, the participants had a median
CD4 count of 418 cells per μL (IQR 256–569). This
was comparable for the two groups. The majority of
patients (72%) had undetectable HIV viral load which was
not significantly different in the two groups (P = 0.318).
HBV viral load was undetectable in 68% of the patients
with HIV‑HBV co‑infection.

Although AST, ALT, and BMI were statistically different in
the two groups, they were not found to have a significant
association with liver fibrosis. There was no statistically
significant difference in current alcohol intake between
the two groups and this was not found to have a significant
association with the presence of liver fibrosis.

Aspartate aminotransferase‑to‑platelet ratio
index score
APRI score was significantly higher in patients with
HIV‑HBV co‑infection compared to those with HIV
monoinfection (P = 0.0068) as shown in the bar graph in
Figure 5. Exactly, 33.4% of the co‑infected patients had an APRI
score of >0.5 compared to 8.6% in the monoinfected group.

The median elastography score was significantly higher in
the HIV‑HBV co‑infected group (P < 0.001). Figure 3a and b
show SWE measurement for one of the patients with HIV‑HBV
co‑infection who had liver fibrosis as per the median score
of 6.35 kPa.

The Pearson’s correlation coefficient between APRI score
and median elastography score was 0.33 (P = 0.0026)
representing moderate correlation. A scatter plot between the
two [Figure 6] showed strong positive correlation for patients
with an APRI score <1. After fitting a linear regression line, for
every unit increase in APRI score, there is a 0.64 (CI = 0.23–1.06)
increase in the median elastography score.

Prevalence of liver fibrosis

DISCUSSION

Overall, the prevalence of liver fibrosis based on an SWE
score >5.6 kPa was 13.3%. The prevalence was significantly
higher (P < 0.0001) in HIV‑HBV co‑infected patients (25.7%)
than in the HIV‑monoinfected patients (7.1%) as shown in
the bar graph in Figure 4.

This study reveals a significantly higher prevalence of liver
fibrosis in patients with HIV‑HBV co‑infection compared
to those with HIV monoinfection as assessed by SWE. HBV
co‑infection was associated with 4.5 times increase in
the prevalence of liver fibrosis. This suggests a significant
impact of HBV infection on the progress of liver disease with
its potential associated morbidity and mortality in patients
with HIV as has been observed in the data collection on
adverse events of anti‑HIV drugs study.[14] HIV co‑infection
with HBV accelerates progression to significant liver fibrosis
which is in keeping with the higher prevalence of liver
fibrosis observed in the HIV‑HBV co‑infected group in our
study.[15,16]

Risk factors for liver fibrosis
In multivariate analysis, HBV co‑infection, low CD4
count (<200 cells/mm3), and detectable viral load was
found to have a significant association with the presence
of advanced liver fibrosis.
HBV co‑infection was associated with 4.5 times increased
risk of having significant fibrosis (CI: 1.3–15.4, P = 0.0086).
Table 1: Baseline characteristics
Characteristic

Median age (years, IQR)
Age >40 years, n (%)
Male sex, n (%)
BMI (kg/m2, IQR)
BMI ≥25 kg/m2, n (%)
Current alcohol intake, n (%)
Median AST, IU (IQR)
Median ALT, IU (IQR)
Platelet count, mean
Median CD4 count (cells/mm3, IQR)
CD4 count <200 cells/mm3, n (%)
HIV viral load category, n (%)
Undetectable (<40 copies/mL)
Detectable (≥40 copies/mL)

HIV monoinfection (n=70)

HIV‑HBV co‑infection (n=35)

P

43.5 (38-50)
45 (64)
38 (54.3)
22.8 (20.6-25.8)
21 (30)
28 (40)
24 (20-31)
23.5 (18-28)
266
426 (312-595)
11 (16)

48 (41-55)
28 (80)
24 (68.6)
21.1 (18.8-22.7)
4 (11)
19 (54)
34 (25-70)
32 (23-40)
246
398 (102-569)
13 (37)

0.0839
0.119
0.161
0.0188
0.051
0.165
0.001
0.002
0.307
0.169
0.025

54 (77)
16 (23)

23 (66)
12 (34)

0.318
0.246

IQR: Interquartile range, BMI: Body mass index, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, HIV: Human immunodeficiency virus, HBV: Hepatitis B virus
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a

b

Figure 3: A 39‑year‑old male with the human immunodeficiency virus hepatitis‑B
virus co‑infection (a) Grayscale ultrasound image of the liver shows a shear
wave elastography acquisition box (arrow) with a high elastography score of
7.4 kPa. (b) A table showing ten liver stiffness measurements readings for the
same patient with a high median elastography score of 6.35 kPa (encircled).

Figure 4: Bar graph comparing prevalence of liver fibrosis in the human
immunodeficiency virus- monoinfected and human immunodeficiency virus
hepatitis‑B virus co‑infected patients show a higher prevalence in the co‑infected
group of approximately 26%.

Figure 5: Bar graph shows distribution of aspartate aminotransferase‑to‑platelet
ratio index score in the human immunodeficiency -virus monoinfected and
human immunodeficiency virus hepatitis‑B virus co‑infected groups and
indicates that only the co‑infected group had patients with an aspartate
aminotransferase‑to‑platelet ratio index score above 1.5.

Prior to this study, evaluation of liver disease in patients with
HIV at our institution was limited to liver enzyme studies.
These tests are however poor markers of liver fibrosis,
especially in HIV‑infected persons as a significant liver fibrosis
may be present in individuals with normal transaminases.[17]
As a result, there may have been underestimation of the
significance of HIV and HBV on liver disease. Though liver
biopsy is traditionally the gold standard for the evaluation of
liver fibrosis, it is not a practical diagnostic tool in this cohort
of patients. Liver elastography offers a noninvasive means
of assessment of liver fibrosis, especially in such patients.
The examination is quick, painless, and highly acceptable to
patients with results obtained almost instantly. It has been
widely validated as a noninvasive means for evaluation of
liver fibrosis.[6]
To our knowledge, only two other studies in Africa, in
Uganda and Nigeria, have assessed liver fibrosis in HIV
patients using elastography. [18,19] Both used transient
elastography as opposed to real‑time SWE used in this study.
The prevalence of significant liver fibrosis in patients with
HIV monoinfection was higher in the Ugandan study (17%)
compared to the Nigerian study (4.7%). Our study found a
prevalence of 7.1% which is slightly higher than that in the
Nigerian study. A study using APRI score found a prevalence
of 8.3% in HIV - monoinfected patients.[20]
5

Figure 6: A scatter plot between median elastography scores and aspartate
aminotransferase‑to‑platelet ratio index scores with a fitted linear regression
line. There was a better correlation between the two for patients with aspartate
aminotransferase‑to‑platelet ratio index score less than 0.5 as opposed to
those with higher scores.

The 25.7% prevalence of liver fibrosis in patients with
HIV‑HBV co‑infection was comparable to the 22.5% found
in the Nigerian study. The average age of subjects was
slightly higher in our study. The median age in our study
was 45 years compared to 34 years for the Nigerian study.
The progression of liver fibrosis is strongly dependent on
age.[21] This is probably related to the higher vulnerability
to environmental factors, especially oxidative stress and
the reduction in immune capacity of an individual as they
age. Although the Nigerian study subjects were ART naive
while those in the current study were not, studies have
shown that ART does not cause significant histological
liver disease and may be protective.[22] The results of our
study are similar to those of the Nigerian study despite
the different elastography techniques used SWE has
been shown to be more accurate and reproducible in the
assessment of liver fibrosis than TE.[9] Monitoring the effect
Journal of Clinical Imaging Science | Vol. 6 | Issue 2 | Apr‑Jun 2016
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of therapy is one the major challenges in the management
of chronic liver diseases. In a study involving patients
with chronic hepatitis‑B infection, there was a significant
decrease in liver elastography measurements compared to
the baseline 1 year posttreatment with entecavir.[23] Liver
elastography, being noninvasive, would thus be useful for
monitoring of liver fibrosis in patients on management for
chronic liver disease.
This study was not powered to assess the effect of potential
confounders such as age, alcohol use, CD4 count, and viral
load on the presence of liver fibrosis. However, low CD4
count and detectable HIV viral load were associated with
the presence of liver fibrosis in our study. Other studies have
shown both to be associated with a significant increase in
the risk of having advanced liver fibrosis.[19,24] These findings
are as a result of the worse clinical progression of liver fibrosis
observed in patients with deeper immunosuppression. This
would support starting of ART earlier so as to prevent rapid
progression of liver disease in HIV‑positive patients.
Although the co‑infected group had a significantly lower
BMI, this was not found to have a significant effect on
the stage of liver fibrosis following multivariate analysis.
Furthermore, weight loss has been postulated to result in
a reduction in abnormal liver enzyme and improvement
in liver fibrosis.[25]
The co‑infected group had significantly higher APRI scores
compared to the monoinfected patients as a result of
higher AST levels in this group. This is in keeping with a
higher prevalence of advanced liver fibrosis observed in the
co‑infected patients using SWE. These findings are similar
to those observed by Post et al., in which HIV patients with
viral co‑infection (HCV or HBV) had higher APRI scores
compared to the monoinfected patients.[26] Although HIV
is associated with thrombocytopenia, high APRI score in
this referenced study was attributed to elevated AST and
not low platelets. AST was normal in the monoinfected
patients in our study, which would explain the lower APRI
scores in this group. Although most patients with HIV
may have normal transaminases despite advanced liver
fibrosis, a high APRI score (which is in essence as a result
of high AST) is associated with increased mortality in these
patients. [26] A comparison between the APRI score and
the median liver elastography scores showed a moderate
correlation between the two with a stronger correlation for
patients with a low APRI score. APRI score is a more readily
available screening tool than SWE as it only requires AST
and platelet count and would, therefore, be very useful in
resource ‑poor settings. The poor correlation in patients
with higher APRI score is likely due to the small number of
6

patients with significant fibrosis as assessed by SWE and
APRI scores and the fact that this study was not powered
to assess for this correlation.

Limitations
Our study had some limitations. First, the elastographic and
APRI score findings in the current study were not compared
to liver biopsy due to technical and ethical challenges. The
SWE cut‑offs used in the study were based on studies done
mainly in Europe with most of the subjects having HCV.
Though there is no reason to believe that the cut‑offs would
be different in the African population, a study to validate
the cut‑offs in African population by comparing SWE with
histology is recommended. Second, the study did not take
into consideration the effect of other potential causes of
liver fibrosis which may be unique to sub‑Saharan Africa, for
example, tropical schistosomiasis and exposure to aflatoxins.
It is however important to state that the study population
was not from an area where these two are endemic in Kenya.
Although the cut‑off of 5.6 kPa is based on the highest
sensitivity and specificity for detecting fibrosis, there is
the inherent risk of misclassifying some patients with high
normal as having fibrosis. The liver elastography scans were
performed by only one radiologist per patient. Although
internal quality evaluation of the technique revealed a high
intra‑ and inter‑observer reproducibility between the two
radiologists of over 90%, lack of two reviewers per patient
in this study is a limitation. SWE also has inherent limitations
with falsely elevated scores seen in patients with acute
hepatitis, cholestasis, and congestive cardiac disease in
the absence of fibrosis which were not controlled for in our
study. Compared to magnetic resonance MR elastography,
SWE has shown moderate correlation and similar diagnostic
performance in the diagnosis of hepatic fibrosis of METAVIR
stage F2 or greater.[27]

CONCLUSION
Given the higher prevalence of liver fibrosis in patients
with HIV‑HBV co‑infection compared to those with HIV
monoinfection, the authors recommend routine monitoring
of this group of patients to check for progression to
cirrhosis. Significant reduction in LSM has been shown to
correlate well with response to therapy and since SWE is
noninvasive, it would form an excellent monitoring tool.
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